Austco Healthcare (AHC) Investor presentation summary
Event summary combining transcript, slides, and related documents.
Investor presentation summary
19 Aug, 2026Company overview and global presence
Founded in Perth in 1986, now operating globally with over 4,500 installations in 56 countries and 6 offices worldwide.
Employs 114 full-time staff, supported by a network of resellers and distributors.
Emphasizes agility, consistent product releases, and R&D investment.
Involves caregivers in product design to ensure fit-for-purpose solutions.
Recent contract wins and strategic expansion
Secured major contracts including $5.0m for New Surrey Hospital, $6.7m for New Saint Paul's, and $2.5m for Encompass.
Won a $1.5m contract with Hospital Sírio-Libanês in LATAM and SGD $2.6m with Mount Elizabeth in Singapore.
Acquired Teknocorp and Amentco, expanding capabilities and market reach.
Added new resellers in Oman, Jordan, Iraq, and UAE, and expanded sales leadership in multiple regions.
Financial performance and growth
FY24 revenue reached $58.2 million, up 39% from FY23, marking an 11-year high.
EBITDA rose 126% to $8.1 million, exceeding guidance, with $3.3m from organic growth and $1.2m from acquisitions.
NPAT increased 213% to $7.1 million, aided by recognition of tax losses.
Gross margin grew 37% to $30.7 million, with a slight margin percentage decline due to lower-margin acquisitions.
Software and SMA revenues rose 9% to $9.3 million, presenting integration opportunities.
Latest events from Austco Healthcare
- Record revenue, profit, and recurring software growth, with strong cash and major contract wins.AHC
H2 2026 - Record revenue, profit, and software growth driven by acquisitions and innovation.AHC
Investor presentation - Record revenue and EBITDA growth, global expansion, and strong cash position drive future outlook.AHC
Investor presentation - Record revenue and profit growth, with strong order backlog and positive growth outlook.AHC
H2 2024 - Record Q1 revenue growth and major contract wins drive strong outlook for continued expansion.AHC
Q1 2025 TU - First-half FY25 revenue and EBITDA are set to surge, boosted by acquisitions and organic growth.AHC
Q2 2025 TU - Record revenue and EBITDA growth, strong profit, and robust order book support future performance.AHC
H1 2025 - Revenue and EBITDA surged year-over-year, with strong cash flow and robust contracted revenue.AHC
Q4 2025 TU - Record revenue and EBITDA growth, strong cash, and robust orders position for continued expansion.AHC
H2 2025